In vitro reversion of amphotericin B resistance in Leishmania donovani by Poloxamer 188

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2190-2192

  Espuelas, S ^a   Legrand, P ^b   Loiseau, P M ^b   Bories, C ^b   Barratt, G ^b   Irache, J M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; POLOXAMER;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMASTIGOTE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; BETAINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; MICROBIAL SENSITIVITY TESTS; POLOXAMER;

EID: 0033929658     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2190-2192.2000     Document Type: Article

References (24)

1. Alléman, E., R. Gurny, and E. Doelker. 1993. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39:173-191.
2. Araujo, F. G., and T. Slifer. 1995. Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii. Antimicrob. Agents Chemother. 39:2696-2701.
3. Berman, J. 1997. Human leishmaniasis: clinical, diagnostic and chemotherapic developments in the last 10 years. Clin. Infect Dis. 24:684-703.
4. Berman, J., and R. Dietze. 1999. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion. Chemotherapy (Basel) 45(Suppl. 1):54-66.
5. Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, F. Kuzoe, L. Pang, K. Weerasuriya, and A. D. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O. 76:25-32.
6. Bogdan, C., A. Gessner, W. Solbach, and M. Röllinghoff. 1996 Invasion, control and persistence of Leishmania parasites. Curr. Opin. Immunol. 8:517-525.
7. Borst, P., and M. Ouellette. 1995. New mechanism of drug resistance in parasitic protozoa. Annu. Rev. Microbiol. 49:427-460.
8. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
9. Croft, S. L., J. A. Urbina, and R. Brun. 1997. Chemotherapy of human leishmaniasis and trypanosomiasis, p. 245-257. In G. Hide, J. C. Mottram, G. H. Coombsand, and P. H. Holmes (ed.), Trypanosomiasis and leishmaniasis. CAB International, Oxon, United Kingdom.
10. Davidson, R. N., L. Di Martino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. Di Caprio, R. J. Wilkinson, and A. D. Bryceson. 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22:938-943.
11. Espuelas, M. S., P. Legrand, M. Chéron, G. Barrat, J.-P. Devissaguet, and J. M. Irache. 1998. Interaction of amphotericin B with polymeric colloids. 1. A spectroscopic study. Colloids Surf. B. 11:141-151.
12. Flick, P. A., and G. E. Gifford. 1984. Comparison of in vitro cell cytotoxicity assays for tumor necrosis factor. J. Immunol. Methods 68:167-173.
13. Haynes, M. P., H. R. Buckley, M. L. Higgins, and R. A. Pieringer. 1994. Synergism between antifungal agents amphotericin B and alkyl glycerol ethers. Antimicrob. Agents. Chemother. 38:1523-1529.
14. Jagganath, C., H. S. Allaudeen, and R. L. Hunter. 1995. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents. Chemother. 39:1349-1354.
15. Kwon, G. S., and T. Okano. 1999. Soluble self assembled block copolymers for drug delivery. Pharm. Res. 16:597-600.
16. Mbongo, N., P. M. Loiseau, M. A. Billion, and M. Robert-Gero. 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 42:352-357.
17. Meyerhoff, A. 1999. U.S. Food and Drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28:42-48.
18. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1997. Enhacement of nitric oxide synthesis by macrophages represents an additional mechanism of action by AmB. Antimicrob. Agents Chemother. 41:1825-1829.
19. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
20. Newman, M. J., J. K. Actor, M. Balussubramanian, and C. Jagannath. 1998. Use of noionic block copolymers in vaccines and therapeutics. Crit. Rev. Ther. Drug Carrier Syst. 15:89-142.
21. Ramos, H., J. Milhaud, B. Eleazar Cohen, and J. Bolard. 1990. Enhanced action of amphotericin B on Leishmania mexicana resulting from heat transformation. Antimicrob. Agents Chemother. 34:1584-1589.
22. Sundar, S., N. K. Agrawal, P. R. Sinha, G. S. Horwith, and H. W. Murray. 1997. Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann. Intern. Med. 127:133-137.
23. United States Pharmacopeial Convention, Inc. 2000. USP 24-NF 19. Poloxamer, p. 2492-2493. United States Pharmacopeial Convention, Inc., Rockville, Md.
24. Yardley, V., and S. L. Croft. 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13:243-248.